Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Novartis' Afinitor fails frontline breast cancer trial

Novartis' Afinitor fails frontline breast cancer trial Afinitor conferred a seven-month improvement in PFS, and while this may warrant further study emerging data for other treatment regimens - such as the combination of Herceptin with Roche's Perjeta

NHS names drugs to be re-evaluated for Cancer Drugs Fund

NHS names drugs to be re-evaluated for Cancer Drugs Fund Kadcyla (trastuzumab emtansine). Breast cancer. Perjeta (pertuzumab). Breast cancer. Sanofi. Jevtana (cabazitaxel).

SMC fails to recommend Roche’s Perjeta

SMC fails to recommend Roche’s Perjeta Says drug is not a cost-effective option in breast cancer. The Scottish Medicines Consortium (SMC) has not recommended Roche's Perjeta for use in the treatment of unresectable breast cancer. ... Perjeta demonstrated "phenomenal" results at the European

BMS taps F-star Alpha for immuno-oncology drug

BMS taps F-star Alpha for immuno-oncology drug FS102 works differently to current HER2-targeted therapies such as Roche's Herceptin (trastuzumab) and Perjeta (pertuzumab), and is being developed specifically to meet the problem of resistance to those drugs.

Strong sales in breast cancer lift Roche revenues

Strong sales in breast cancer lift Roche revenues New products Perjeta and Kadcyla lead growth. Rocketing sales of Roche's new breast cancer drugs Perjeta and Kadcyla suggest they will cushion any impact from biosimilar competition to Herceptin, which ... Last month, Roche reported new clinical data

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics